Journal
ONCOGENE
Volume 39, Issue 36, Pages 5811-5824Publisher
SPRINGERNATURE
DOI: 10.1038/s41388-020-01405-w
Keywords
-
Funding
- NIH [R01CA215733, R01CA226888, P01CA114046, P50CA174523, P30CA010815]
- Department of Defense Melanoma Research Program [W81XWH-20-1-0356]
- PA Department of Health
- Martha W. Rogers Trust
Ask authors/readers for more resources
Telomere maintenance via telomerase reactivation is a nearly universal hallmark of cancer cells which enables replicative immortality. In contrast, telomerase activity is silenced in most adult somatic cells. Thus, telomerase represents an attractive target for highly selective cancer therapeutics. However, development of telomerase inhibitors has been challenging and thus far there are no clinically approved strategies exploiting this cancer target. The discovery of prevalent mutations in theTERTpromoter region in many cancers and recent advances in telomerase biology has led to a renewed interest in targeting this enzyme. Here we discuss recent efforts targeting telomerase, including immunotherapies and direct telomerase inhibitors, as well as emerging approaches such as targetingTERTgene expression driven byTERTpromoter mutations. We also address some of the challenges to telomerase-directed therapies including potential therapeutic resistance and considerations for future therapeutic applications and translation into the clinical setting. Although much work remains to be done, effective strategies targeting telomerase will have a transformative impact for cancer therapy and the prospect of clinically effective drugs is boosted by recent advances in structural models of human telomerase.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available